Harmony Biosciences (HRMY) Tops Q3 EPS by 12c, provides guidance

Harmony Biosciences (NASDAQ: HRMY) reported Q3 EPS of $0.79, $0.12 better than the analyst estimate of $0.67. Revenue for the quarter came in at $186.04 million versus the consensus estimate of $186.01 million.

GUIDANCE:

Harmony Biosciences sees FY2024 revenue of $700-720 million, versus the consensus of $710.1 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Electra Therapeutics files for proposed IPO
• IP Strategy Holdings receives Nasdaq noncompliance notice over late 10-Q